echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Teva and Yourui jointly announce the listing of Cunda (bendamustine hydrochloride) in China

    Teva and Yourui jointly announce the listing of Cunda (bendamustine hydrochloride) in China

    • Last Update: 2019-05-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Shanghai May 29, 2019 / Meitong news agency / -- tyvee pharmaceutical information consulting (Shanghai) Co., Ltd (global leader in generic and specialty medicine field Teva's branch in China in Israel) and Yurui Pharmaceutical Technology (a new special medicine company headquartered in China) jointly announced the launch of Cunda ® (bendamoxetine hydrochloride for injection) products in China on May 26, 2019 Cunda ® is suitable for inert B-cell non-Hodgkin's lymphoma (NHL) that develops during or after rituximab or rituximab regimens Teva successfully conducted clinical trials in China and obtained positive results in China's Cunda ® phase 3 study in May 2016 On December 17, 2018, Cunda was approved by the National Drug Administration of China (nmpa) "We are very pleased to be able to provide this innovative cancer treatment drug to China to meet the current unmet needs of patients," said Larry E merizalde, general manager of Teva China This represents an important step towards Teva's long-term goal in the Chinese market We look forward to continue to provide high-quality and innovative drugs, contribute to "healthy China 2030", and take improving the health of the Chinese people as the ultimate goal " Relying on its global expertise and innovative product portfolio in three target treatment areas (tumor, respiratory system and central nervous system (CNS)) in China, Teva company launched the first innovative drug, Cunda ®, which was launched on May 26 in Chenggong, Zhengzhou, China Teva chooses to cooperate with yourui Pharmaceutical Technology Co., Ltd to provide exclusive promotion for the Chinese market "We are very pleased to be able to work with Teva in China and launch this much-needed cancer treatment product to Chinese patients," said Mark g lotter, founder of yourui pharmaceutical In March 2008, Cunda ® was approved by the US FDA for the treatment of chronic lymphoblastic leukemia (CLL) The efficacy relative to the first-line treatment (except for nitrogen mustard benzoate) has not been determined Treanda ® was again approved in October 2008 for the treatment of patients with inert B-cell non Hodgkin's lymphoma (NHL) who progressed during or within 6 months of treatment with rituximab or rituximab containing regimens Cunda ® has a unique chemical structure, which can be combined with alkylation groups and purine like benzimidazole components Although the exact mechanism of action of Cunda is still unknown, bendamostine has activity on resting and dividing cells Preclinical studies have shown that Cunda ® may cause cell death through a process known as apoptosis (programmed cell death) and other cell death pathways (non apoptotic pathways) that disrupt normal cell division (known as mitotic dysfunction) About inert non-Hodgkin's lymphoma (NHL), non-Hodgkin's lymphoma (NHL) is a disease in which cancer cells form in the lymph tissue of the body Because the lymphoid tissue is all over the body, NHL can appear in almost any part of the body and spread to almost any tissue or organ There are about 60 different types of NHL, which are formed by B cells or T cells Most non Hodgkin's lymphomas (80% to 90%) are formed by B cells NHL is usually divided into two categories - inertia and aggressiveness Inert non-Hodgkin's lymphoma (inhl) is a slow-growing lymphoma The median survival time of patients with inert lymphoma was about 10 years Inert lymphoma usually responds to treatment but recurs frequently About nuance (yourui Pharmaceutical Technology) yourui company is a leading new specialty drug company in China, with its headquarters in Shanghai The company is supported by well-known venture capital and private equity institutions in the industry In recent years, a series of product introduction and M & a business have made the company develop rapidly In addition to the cooperation agreement with Teva on "Cunda ®", Yurui has expanded its product portfolio in China through a series of licensing and acquisition transactions with other large multinational (MNC) companies The company is composed of a group of experienced managers who have a good understanding of the Chinese market and have a good past performance in oncology Yurui hopes to further expand its product portfolio in the field of tumor and immunology, and regards "Cunda ®" as its first product in this important treatment field in China About Teva Teva, which has been developing and producing drugs that can improve people's lives for more than a century We are a global leader in generic and specialty drugs, with more than 35000 products in our portfolio, covering almost every area of treatment Around 200 million people use Teva's drugs every day around the world, and we are served by one of the largest and most complex supply chains in the pharmaceutical industry In addition to our business in generics, we have important innovative research and operations to support our ongoing development of a portfolio of specialty and biopharmaceutical products.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.